Compare NNY & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NNY | MNOV |
|---|---|---|
| Founded | 1987 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 154.3M | 137.8M |
| IPO Year | N/A | 2004 |
| Metric | NNY | MNOV |
|---|---|---|
| Price | $7.97 | $1.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.25 |
| AVG Volume (30 Days) | 72.1K | ★ 801.4K |
| Earning Date | 01-01-0001 | 11-11-2026 |
| Dividend Yield | ★ 4.04% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,360,807.00 |
| Revenue This Year | N/A | $78.20 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 194.15 |
| 52 Week Low | $7.55 | $1.17 |
| 52 Week High | $8.94 | $3.90 |
| Indicator | NNY | MNOV |
|---|---|---|
| Relative Strength Index (RSI) | 52.81 | 38.52 |
| Support Level | $7.55 | $1.29 |
| Resistance Level | $8.75 | $1.86 |
| Average True Range (ATR) | 0.15 | 0.17 |
| MACD | 0.04 | -0.10 |
| Stochastic Oscillator | 71.93 | 3.32 |
Nuveen New York Municipal Value Fund Inc. is a diversified closed-end management investment company. The Fund seeks to provide current income exempt from regular federal, New York State, and New York City income taxes, and from the federal alternative minimum tax for individuals, while enhancing portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds considered underrated, undervalued, or from undervalued municipal market sectors. It may invest in municipal securities such as lease obligations and certificates of participation, which provide an undivided interest in pools of municipal leases or installment purchase agreements.
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.